Valuation: MaaT Pharma

Market Cap 1.9Cr 2.14Cr 1.78Cr 1.62Cr 3.05Cr 205.92Cr 3.08Cr 21Cr 8.33Cr 105.27Cr 8.04Cr 7.87Cr 337.85Cr P/E 2026 *
-0.53x
P/E 2027 * -0.91x
Enterprise Value 3.28Cr 3.7Cr 3.06Cr 2.79Cr 5.27Cr 355.28Cr 5.32Cr 37Cr 14Cr 181.62Cr 14Cr 14Cr 582.89Cr EV / Sales 2026 *
3.37x
EV / Sales 2027 * 1.8x
Free-Float
36.81%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 01/01/2014
Director of Finance/CFO 59 01/11/2024
Chief Tech/Sci/R&D Officer - 24/06/2024
Director TitleAgeSince
Director/Board Member - 01/01/2014
Director/Board Member 57 01/01/2014
Chairman - 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.14Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+21.92%+74.60% 5.74TCr
+0.89%-0.63%+4.28%+34.51% 4.76TCr
+0.36%+0.81%+352.17%+689.61% 4.43TCr
-0.96%-4.50%+26.36%+33.18% 4.25TCr
-0.20%-0.77%+3.74%+100.60% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.63%+19.50% 2.85TCr
+0.05%-1.64%-7.28%-14.06% 2.43TCr
Average -0.20%-0.59%+54.39%+120.28% 4.34TCr
Weighted average by Cap. +0.12%-0.84%+58.77%+129.91%

Financials

2026 *2027 *
Net sales 97.51L 1.1Cr 91.01L 82.95L 1.56Cr 105.5Cr 1.58Cr 11Cr 4.27Cr 54Cr 4.12Cr 4.03Cr 173.09Cr 2.89Cr 3.25Cr 2.7Cr 2.46Cr 4.63Cr 312.44Cr 4.68Cr 33Cr 13Cr 159.72Cr 12Cr 12Cr 512.61Cr
Net income -3.17Cr -3.57Cr -2.96Cr -2.7Cr -5.09Cr -342.92Cr -5.13Cr -36Cr -14Cr -175.3Cr -13Cr -13Cr -562.61Cr -1.53Cr -1.72Cr -1.43Cr -1.3Cr -2.46Cr -165.66Cr -2.48Cr -17Cr -6.7Cr -85Cr -6.47Cr -6.33Cr -271.79Cr
Net Debt 1.38Cr 1.55Cr 1.29Cr 1.17Cr 2.21Cr 149.36Cr 2.24Cr 16Cr 6.04Cr 76Cr 5.83Cr 5.71Cr 245.05Cr 3.28Cr 3.7Cr 3.07Cr 2.79Cr 5.27Cr 355.41Cr 5.32Cr 37Cr 14Cr 181.69Cr 14Cr 14Cr 583.12Cr
Logo MaaT Pharma
MaaT Pharma is a late-stage biotechnology company and a leader in the development of intestinal microbiota-based drugs designed to modulate the immune system of cancer patients and improve their survival. A pioneer in its field, MaaT Pharma is developing the first immunomodulatory drug candidate based on intestinal microbiota in oncology, currently in phase 3 clinical evaluation. Thanks to its proprietary pooling (combining donations of healthy microbiota) and microbial co-culture technologies, MaaT Pharma is developing standardised drugs with high bacterial diversity, aimed at improving the survival of cancer patients.
Employees
56
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.010EUR
Average target price
6.500EUR
Spread / Average Target
+543.56%

Annual profits - Rate of surprise